// App-Quantinova.ai

TPS4577 : BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Elaine Kilgour

  • Richard Mather

  • Anne Galer

  • Hendrik-Tobias Arkenau

  • Andrew Farnsworth

  • Jonathan Wilde

  • Jayantha Ratnayake

  • Donal Landers

Medical Centers

  • Barts Cancer Institute, Barts Health, and The Royal Free London NHS Foundation Trust, London, United Kingdom

  • AstraZeneca Oncology Innovative Medicines, Macclesfield, United Kingdom

  • AstraZeneca, Royston, United Kingdom

  • AstraZeneca, Macclesfield, United Kingdom

  • Sarah Cannon Research Institute UK, London and University College London Hospitals., London, United Kingdom

  • Global Medicine Development, AstraZeneca, Alderly Park, United Kingdom

  • AstraZeneca Plc., Macclesfield, Cheshire, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • MYCN proto-oncogene, bHLH transcription factor

  • Programmed death-ligand 1

  • Ribosomal Protein S27a

Drug/Treatment

  • Durvalumab

  • Olaparib

  • AZD-1775

  • AZD-4547

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02546661

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved